Branded Generics

Our Branded Generics division develops, manufactures and markets products that are the therapeutic equivalent to their brand name counterparts. IMS Health, which began tracking and reporting on branded generics in 2002, defines the category as including prescription "products that are either novel dosage forms of off-patent products produced by a manufacturer that is not the originator of the molecule, or a molecule copy of an off-patent product with a trade name." This definition is used by both the FDA and the United Kingdom's National Health Service (NHS).

Emerging markets are an area of high focus for Valeant and we currently have operations in certain countries in Central Europe and Latin America. This business is focused on branded generic pharmaceuticals which are bioequivalent to original products but are marketed under the Company's brand names. Branded generics are an attractive business for Valeant with low research and development costs and sustainable sales that do not face the patent expiry of traditional pharmaceutical compounds.

Our portfolio for this business includes products we have internally developed, products we have licensed, and products we distribute for third parties. Our branded generics cover a broad range of treatments including antibiotics, antifungal medications, and diabetic therapies among many others.

Please view our Product Table for a list of Valeant's branded generic products.